全文获取类型
收费全文 | 704篇 |
免费 | 32篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 36篇 |
妇产科学 | 18篇 |
基础医学 | 89篇 |
口腔科学 | 5篇 |
临床医学 | 56篇 |
内科学 | 117篇 |
皮肤病学 | 2篇 |
神经病学 | 38篇 |
特种医学 | 26篇 |
外科学 | 189篇 |
综合类 | 25篇 |
预防医学 | 33篇 |
眼科学 | 12篇 |
药学 | 16篇 |
中国医学 | 5篇 |
肿瘤学 | 62篇 |
出版年
2024年 | 1篇 |
2023年 | 7篇 |
2022年 | 21篇 |
2021年 | 24篇 |
2020年 | 10篇 |
2019年 | 25篇 |
2018年 | 31篇 |
2017年 | 10篇 |
2016年 | 21篇 |
2015年 | 10篇 |
2014年 | 26篇 |
2013年 | 28篇 |
2012年 | 42篇 |
2011年 | 68篇 |
2010年 | 47篇 |
2009年 | 22篇 |
2008年 | 47篇 |
2007年 | 53篇 |
2006年 | 45篇 |
2005年 | 35篇 |
2004年 | 41篇 |
2003年 | 35篇 |
2002年 | 33篇 |
2001年 | 12篇 |
2000年 | 8篇 |
1999年 | 13篇 |
1998年 | 6篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1995年 | 1篇 |
1994年 | 3篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有739条查询结果,搜索用时 9 毫秒
11.
12.
Mahmoud?A.?Elshenawy M.?Shahzad Rauf Tusneem?A.M.?Elhassan Irfan?Maghfoor Saad?AkhtarEmail authorView authors OrcID profile 《Annals of hematology》2018,97(7):1229-1240
Hodgkin lymphoma (HL) patients failing after high dose chemotherapy (HDC) and auto-SCT have a poor outcome. Some patients may still benefit from further treatments. From 1996 to 2016, 137 HL patients (39.5%) out of 347 transplanted experienced post auto-SCT failure. Males/female 61%:39%, median age at auto-SCT 23.4 years and median follow-up 55.6 months (9–153). Type of failure was progressive (46%), relapsed (35%) or persistent disease/refractory disease (19%). Median overall survival (OS) from the time of failure is 20 months; 35 patients (25.5%) are alive. One hundred and four patients received treatment; the response rate was 45%; complete remission in 41 (30%) and partial remission in 21 (15%) patients. 1st interventions post auto-SCT were chemotherapy (39%), radiation therapy (35%) or best supportive care (24%). Twenty-seven patients with 2nd-SCT (allogeneic (15), auto-SCT (2)) and/or brentuximab (18 patients) had superior OS (50.6 months) vs other treatments (22.5 months, P value 0.037). COX regression multivariate analysis identified post auto-SCT treatment failure before 12 months (hazard ratio (HR) 3.37, CI 1.7–6.6, P value <?0.001), presence of B symptoms (HR 2.55, CI 1.4–4.6, P value 0.002), stages III–IV (HR 2.7, CI 1.5–4.9, P value 0.001), albumin <?4 g/dl (HR 1.76, CI 1.1–2.9, P value 0.027) and tumor >?5 cm (HR 1.1.9, CI 1.13–3.25, P value 0.015) as significant risk factors; P value <?0.001. KM OS with 0–1 factor (148.6 months): 2 factors (23.6 months) and 3–5 factors (9.4 months) (P value <?0.001). OS was 63%:25%:7% respectively with 0–1:2:3–5 factors respectively (P value <?0.001). Despite high-risk factors, 2nd-SCT/brentuximab use post HDC auto-SCT failure may result in durable survival. 相似文献
13.
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital 总被引:12,自引:13,他引:12
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Pui CH Sandlund JT Pei D Campana D Rivera GK Ribeiro RC Rubnitz JE Razzouk BI Howard SC Hudson MM Cheng C Kun LE Raimondi SC Behm FG Downing JR Relling MV Evans WE;Total Therapy Study XIIIB at St Jude Children's Research Hospital 《Blood》2004,104(9):2690-2696
St Jude Total Therapy Study XIIIB for childhood acute lymphoblastic leukemia (ALL) incorporated more stringent risk classification, early intensification of intrathecal chemotherapy, reinduction treatment, and the addition of dexamethasone to postremission therapy to increase the proportion of event-free survivors without jeopardizing their quality of life. Cranial irradiation was reserved for the 12% of patients who had T-cell ALL and a presenting leukocyte count of 100 x 10(9)/L or more, or CNS-3 (5 or more leukocytes/microL with identifiable blast cells in an atraumatic sample or the presence of cranial nerve palsy) status. Among the 247 consecutive patients enrolled in the study, 117 were classified as having lower-risk leukemia and received mainly antimetabolite-based continuation therapy; the 130 cases with higher-risk leukemia received more intensive continuation chemotherapy with multiple drug pairs administered in weekly rotation. The 5-year event-free survival estimate was 80.8% +/- 2.6% (SE); the 8-year rate was 78.6% +/- 5.8%. The 5-year cumulative risk of an isolated central nervous system (CNS) relapse was 1.7% +/- 0.8%, and that of isolated plus combined CNS relapse was 3.0% +/- 1.1%. The 5-year cumulative risks of etoposide-related myeloid malignancies were 1.8% +/- 1.3% in the lower-risk patients who received a cumulative dose of 1.2 g/m(2) and 5.0% +/- 2.0% in the higher-risk patients who received a cumulative dose of up to 14.4 g/m(2) (P = .18). Independent adverse prognostic features included the presence of MLL-AF4 or BCR-ABL fusion gene and minimal residual leukemia of 0.01% or more at the end of the 6-week remission induction phase. Our results suggest the efficacy of early intensification of intrathecal chemotherapy and provide the basis for studies omitting cranial irradiation altogether. 相似文献
14.
Nicholas J. Clark Bassem T. Elhassan 《Current reviews in musculoskeletal medicine》2018,11(1):141-149
Purpose of Review
This review aims to describe the tendon transfer options for treating irreparable rotator cuff tears (RCTs). Options for transfer include latissimus dorsi and lower trapezius transfers for posterior-superior RCTs and pectoralis major and latissimus dorsi transfer for anterior-superior RCTs.Recent Findings
While the latissimus dorsi tendon transfer has historically been performed for posterosuperior RCTs, the lower trapezius transfer is a more anatomic option and has demonstrated promising results in recent studies. Similarly, the pectoralis major transfer has historically been the tendon transfer of choice for anterosuperior RCTs. However, the latissimus dorsi tendon transfer has recently been shown to be a safe and anatomic tendon transfer for subscapularis insufficiency.Summary
The treatment of irreparable RCTs involves complex decision making. Tendon transfer procedures can restore the glenohumeral joint force couples, allowing restoration of near-normal shoulder kinematics. Benefits include reliable pain relief, increased function, and increased strength. Proper selection of donor tendon is crucial, and the principles of tendon transfer procedures must be adhered to for maximal benefit.15.
Levels of somatostatin were investigated in the ankles and spinal cords of rats suffering from acute and chronic adjuvant arthritis. As measured by radioimmunoassay, somatostatin showed significantly higher concentrations only in chronic arthritic ankles. No significant difference was observed in somatostatin levels between the spinal cords of normal and arthritic groups. Using immunohistochemical labeling and electron microscopy, we observed increased somatostatin labeling in the mature bone matrix, monocytes, and polymorphonuclear cells of bone marrow and macrophage-like synovial cells of chronically arthritic rats. Understanding the mechanism(s) which lead to increased somatostatin in chronic arthritic joints may result in more effective treatment methods. 相似文献
16.
Bassem R. Haddad Lei Gu Tuomas Mirtti Ayush Dagvadorj Paraskevi Vogiatzi David T. Hoang Renu Bajaj Benjamin Leiby Elyse Ellsworth Shauna Blackmon Christian Ruiz Mark Curtis Paolo Fortina Adam Ertel Chengbao Liu Hallgeir Rui Tapio Visakorpi Lukas Bubendorf Marja T. Nevalainen 《The American journal of pathology》2013,182(6):2264-2275
17.
18.
19.
20.
Emilie Cornec-Le Gall Marie-Pierre Audrézet Annick Rousseau Maryvonne Hourmant Eric Renaudineau Christophe Charasse Marie-Pascale Morin Marie-Christine Moal Jacques Dantal Bassem Wehbe Régine Perrichot Thierry Frouget Cécile Vigneau Jér?me Potier Philippe Jousset Marie-Paule Guillodo Pascale Siohan Nazim Terki Théophile Sawadogo Didier Legrand Victorio Menoyo-Calonge Seddik Benarbia Dominique Besnier Hélène Longuet Claude Férec Yannick Le Meur 《Journal of the American Society of Nephrology : JASN》2016,27(3):942-951
The course of autosomal dominant polycystic kidney disease (ADPKD) varies among individuals, with some reaching ESRD before 40 years of age and others never requiring RRT. In this study, we developed a prognostic model to predict renal outcomes in patients with ADPKD on the basis of genetic and clinical data. We conducted a cross-sectional study of 1341 patients from the Genkyst cohort and evaluated the influence of clinical and genetic factors on renal survival. Multivariate survival analysis identified four variables that were significantly associated with age at ESRD onset, and a scoring system from 0 to 9 was developed as follows: being male: 1 point; hypertension before 35 years of age: 2 points; first urologic event before 35 years of age: 2 points; PKD2 mutation: 0 points; nontruncating PKD1 mutation: 2 points; and truncating PKD1 mutation: 4 points. Three risk categories were subsequently defined as low risk (0–3 points), intermediate risk (4–6 points), and high risk (7–9 points) of progression to ESRD, with corresponding median ages for ESRD onset of 70.6, 56.9, and 49 years, respectively. Whereas a score ≤3 eliminates evolution to ESRD before 60 years of age with a negative predictive value of 81.4%, a score >6 forecasts ESRD onset before 60 years of age with a positive predictive value of 90.9%. This new prognostic score accurately predicts renal outcomes in patients with ADPKD and may enable the personalization of therapeutic management of ADPKD. 相似文献